Shares of Intrexon Corp (NASDAQ:XON) have been assigned a consensus rating of “Hold” from the six brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.00.
A number of equities analysts have weighed in on the stock. Bank of America dropped their target price on shares of Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research note on Friday, August 9th. ValuEngine raised shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Northland Securities reaffirmed a “hold” rating and issued a $10.00 target price on shares of Intrexon in a research note on Monday, August 12th. Finally, BidaskClub downgraded shares of Intrexon from a “hold” rating to a “sell” rating in a research note on Tuesday, October 22nd.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Third Security LLC increased its stake in Intrexon by 10.0% in the second quarter. Third Security LLC now owns 74,553,246 shares of the biotechnology company’s stock valued at $571,078,000 after purchasing an additional 6,762,077 shares in the last quarter. BlackRock Inc. increased its stake in Intrexon by 14.5% in the second quarter. BlackRock Inc. now owns 7,357,181 shares of the biotechnology company’s stock valued at $56,355,000 after purchasing an additional 932,636 shares in the last quarter. Vanguard Group Inc. increased its stake in Intrexon by 33.8% in the second quarter. Vanguard Group Inc. now owns 6,672,135 shares of the biotechnology company’s stock valued at $51,109,000 after purchasing an additional 1,686,028 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Intrexon by 138.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after purchasing an additional 1,572,077 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. increased its stake in Intrexon by 133.9% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,704,014 shares of the biotechnology company’s stock valued at $20,713,000 after purchasing an additional 1,548,194 shares in the last quarter. 75.73% of the stock is owned by institutional investors and hedge funds.
NASDAQ:XON traded up $0.11 on Wednesday, reaching $5.30. The stock had a trading volume of 751,800 shares, compared to its average volume of 1,875,004. The firm has a market cap of $820.08 million, a P/E ratio of -3.87 and a beta of 2.35. Intrexon has a 1-year low of $3.95 and a 1-year high of $13.69. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.55 and a quick ratio of 3.20. The stock’s fifty day simple moving average is $5.83.
Intrexon (NASDAQ:XON) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.05. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. The firm had revenue of $35.99 million for the quarter, compared to analyst estimates of $29.62 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The company’s revenue for the quarter was down 20.6% compared to the same quarter last year. As a group, equities analysts anticipate that Intrexon will post -0.9 EPS for the current year.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
See Also: What is meant by holder of record?
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.